Here’s why PAR is worth watching now more than ever?

When thinking of a biotech market mover Paradigm Biopharmaceuticals (ASX: PAR) instantly comes to mind. Paradigm, through its repurposed drug Zilosul, aims to alleviate the suffering and cartilage degradation of Osteoarthritis. PAR’s impressive clinical developments in osteoarthritis and 240% surge in 2019 captivated both the scientific and investment world.…

Was Winx safer than an investment fund ?

Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area.

For the enjoyment of aussie punters across Australia , I wanted to write a less serious article that I think alot of people will enjoy .…